MAP3K4 Polyclonal antibody

MAP3K4 Polyclonal Antibody for WB, IF/ICC, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse, rat

Applications

WB, IF/ICC, ELISA

Conjugate

Unconjugated

Cat no : 21610-1-AP

Synonyms

KIAA0213, MAP three kinase 1, MAP3K4, MAPK/ERK kinase kinase 4, MAPKKK4, MEK kinase 4, MEKK 4, MEKK4, MTK1, PRO0412


☆対象製品が30%オフ!組換えタンパク質&免染用試薬 >>> キャンペーン実施中!


Tested Applications

Positive WB detected inK-562 cells
Positive IF/ICC detected inHela cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:1000-1:4000
Immunofluorescence (IF)/ICCIF/ICC : 1:10-1:100
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

Published Applications

IFSee 1 publications below

Product Information

The immunogen of 21610-1-AP is MAP3K4 Fusion Protein expressed in E. coli.

Tested Reactivity human, mouse, rat
Cited Reactivity human
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen MAP3K4 fusion protein Ag16254 相同性解析による交差性が予測される生物種
Full Name mitogen-activated protein kinase kinase kinase 4
Calculated molecular weight 1608 aa, 182 kDa
Observed molecular weight 170-180 kDa
GenBank accession numberBC146770
Gene symbol MAP3K4
Gene ID (NCBI) 4216
RRIDAB_10804775
Conjugate Unconjugated
Form Liquid
Purification MethodAntigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Protocols

Product Specific Protocols
WB protocol for MAP3K4 antibody 21610-1-APDownload protocol
IF protocol for MAP3K4 antibody 21610-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanIF

J Gene Med

Construction and validation of molecular subtype and signature of immune cell-related telomeric genes and prediction of prognosis and immunotherapy efficacy in ovarian cancer patients

Authors - Lele Ling